NDAORALTABLETPriority Review
Approved
Jul 2018
Lifecycle
Peak
Competitive Pressure
30/100
Data completeness
3/8 — Basic
Priority Review
Drug data last refreshed 20h ago · AI intelligence enriched 2w ago
AI summarySynthesized from FDA + DailyMed + ClinicalTrials.gov data
KRINTAFEL (tafenoquine succinate) is an oral small-molecule antimalarial indicated for the treatment and prevention of malaria, particularly for pre-exposure prophylaxis and post-exposure radical cure. It is a prodrug that is bioactivated to active metabolites targeting the parasite. The drug is primarily used for travelers and at-risk populations in malaria-endemic regions.
$0.003BPart D
PeakPeak-stage product with limited Part D penetration suggests early-stage commercial buildout or niche market positioning; brand team likely focused on specialty/travel medicine channels.
Mechanism of Action
Mechanism of action data is being enriched from DailyMed and FDA sources. Check back soon for updated drug intelligence.
Indications
Indication data is being enriched from DailyMed and FDA labeling. Check back soon for approved therapeutic uses.
Career Relevance
Zero linked job openings suggest KRINTAFEL operates as a specialized, mature brand with small dedicated team or integration into broader GSK portfolio management. Roles available are likely in specialty/travel medicine channels requiring niche expertise in tropical medicine and travel health.
Brand ManagerField Sales Representative
Worked on KRINTAFEL at GSK? Share your interview experience or compensation data (+7 days Pro)
Data Sources
- Drug label: DailyMed / FDA
- Clinical trials: ClinicalTrials.gov
- Patent data: FDA Orange Book
- Spending data: CMS Medicare
The information on this page is for informational purposes only and should not be used as a substitute for professional medical advice. Drug information is sourced from FDA, DailyMed, and other government databases. Adverse event data from FAERS does not establish causation. Always consult a healthcare professional for medical decisions.